Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Abeona Therapeutics (ABEO) over the last 14 years, with Q3 2025 value amounting to $5.2 million.

  • Abeona Therapeutics' Cash from Financing Activities rose 182675.59% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 7390.21%. This contributed to the annual value of $104.1 million for FY2024, which is 18102.38% up from last year.
  • Per Abeona Therapeutics' latest filing, its Cash from Financing Activities stood at $5.2 million for Q3 2025, which was up 182675.59% from $10.5 million recorded in Q2 2025.
  • Abeona Therapeutics' Cash from Financing Activities' 5-year high stood at $73.7 million during Q2 2024, with a 5-year trough of -$299000.0 in Q3 2024.
  • For the 5-year period, Abeona Therapeutics' Cash from Financing Activities averaged around $13.8 million, with its median value being $6.6 million (2023).
  • The largest annual percentage gain for Abeona Therapeutics' Cash from Financing Activities in the last 5 years was 63610000.0% (2024), contrasted with its biggest fall of 10130.14% (2024).
  • Abeona Therapeutics' Cash from Financing Activities (Quarter) stood at $16.3 million in 2021, then soared by 161.87% to $42.8 million in 2022, then plummeted by 82.54% to $7.5 million in 2023, then dropped by 28.83% to $5.3 million in 2024, then dropped by 2.84% to $5.2 million in 2025.
  • Its Cash from Financing Activities stands at $5.2 million for Q3 2025, versus $10.5 million for Q2 2025 and $6.8 million for Q1 2025.